[The evaluation of cilazapril efficacy in patients with stable arterial hypertension (a randomized study)]

Terapevticheskii Arkhiv
|January 1, 1995
PubMed

Insights

Cilazapril showed limited antihypertensive effects in patients with stable arterial hypertension, particularly those with higher mean arterial pressure. Hemodynamic improvements were observed only in patients with elevated end-diastolic left ventricular volume.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Stable arterial hypertension (AH) affects a significant portion of the adult population.
  • Effective antihypertensive medications are crucial for managing AH and preventing complications.

Purpose of the Study:

  • To evaluate the efficacy of cilazapril in patients with stable arterial hypertension.
  • To assess the dose-dependent effects of cilazapril on hemodynamics.

Main Methods:

  • A randomized study involving 34 patients with stable arterial hypertension.
  • Patients were randomized based on mean arterial pressure (MAP), end-diastolic LV volume, and cardiac output.
  • Cilazapril was administered at doses of 2.5 mg/day and 5 mg/day.

Main Results:

  • The antihypertensive effect was insufficient in most patients with MAP ranging from 120-135 mm Hg and 136-150 mm Hg, with diastolic pressure remaining above 94 mm Hg.
  • No dose-effect relationship was observed regarding hemodynamics.
  • Hemodynamic benefits were primarily noted in patients with end-diastolic LV volume greater than 5.0-5.7 cm.

Conclusions:

  • Cilazapril demonstrated limited efficacy in lowering blood pressure in the majority of patients with stable arterial hypertension, irrespective of the dose.
  • The drug's hemodynamic benefits were restricted to a subgroup of patients with specific baseline end-diastolic left ventricular volumes.

Related Concept Videos

Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...